BioMarin Pharmaceutical Inc
F:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioMarin Pharmaceutical Inc
F:BM8
|
US |
Intrinsic Value
The intrinsic value of 
BioMarin Pharmaceutical Inc (BM8) under the Base Case is 50.43 EUR per share.
Compared with the current market price of 48.88 EUR, the stock appears
Undervalued by 3% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What BioMarin Pharmaceutical Does
BioMarin Pharmaceutical makes prescription medicines for rare genetic diseases, especially conditions that affect children and often need lifelong treatment. Its products include enzyme replacement therapies, biologic drugs, and gene therapies designed to treat the underlying cause of certain inherited disorders rather than just easing symptoms.
- Headquarters
- United States of America US
- Employees
- 3 221
- IPO date
- Jul 23, 1999
Revenue & Expenses Breakdown
BioMarin Pharmaceutical Inc
Earnings Waterfall
BioMarin Pharmaceutical Inc
The intrinsic value for BioMarin Pharmaceutical Inc (BM8) under the Base Case is 50.43 EUR.
Compared with the current market price of 48.88 EUR, the stock appears Undervalued by 3% .